Pulse Biosciences ramps R&D spending as commercialization of nsPFA technology begins

Pulse Biosciences (NASDAQ:PLSE) reported its financial results for the first quarter of 2026, marking a pivotal transition from a pure-research entity to early-stage commercialization of its proprietary nPulse™ technology.

The company, which specializes in Nanosecond Pulsed Field Ablation (nsPFA), recorded total revenue of $0.4 million for the quarter, comprised of both capital equipment and disposable product sales.

The quarterly performance was characterized by a significant step-up in operational spending aimed at securing regulatory clearances and clinical validation.

Total GAAP costs and expenses rose to $19.6 million, up from $18 million in the prior-year period.

On a non-GAAP basis, which adjusts for stock-based compensation and one-time items, expenses climbed to $17.4 million, a $4.7 million increase over the same period in 2025.

Management attributed the higher burn rate primarily to expanded investment in clinical trials and the development of its nsPFA cardiac and surgical applications.

The increased investment led to a wider GAAP net loss of $18.6 million, or ($16.4) million on a non-GAAP basis.

Cash used in operating activities totaled $14.6 million for the quarter, consistent with the company's recent spending trajectory as it moves through various clinical milestones.

As of March 31, 2026, Pulse Biosciences held $68.3 million in cash and cash equivalents, a decrease from $119.3 million a year earlier.

To support its ongoing capital needs, the company maintains approximately $60 million in availability under an "at-the-market" (ATM) equity program, alongside an effective $200 million shelf registration statement.